| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 04/18/2002 | WO2002031181A2 Flea synaptic vesicle nucleic acid molecules, proteins and uses thereof |
| 04/18/2002 | WO2002031109A2 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | WO2002030958A2 Casein peptide fragments with growth-influencing activity on cell cultures |
| 04/18/2002 | WO2002030957A1 Peptide-based gemini surfactant compounds facilitating the transfer into cells |
| 04/18/2002 | WO2002030922A2 Dioxolane analogs for improved inter-cellular delivery |
| 04/18/2002 | WO2002030397A1 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors |
| 04/18/2002 | WO2002002488A3 Methods and compounds for modulating nuclear receptor coactivator binding |
| 04/18/2002 | WO2001053330A3 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them |
| 04/18/2002 | US20020045575 Treating inflammatory, autoimmune diseases, including graft-versus-host disease and enhancement of graft/tissue survival following transplant |
| 04/18/2002 | US20020045231 Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies |
| 04/18/2002 | US20020045189 Polypeptide and process for measuring living body components using the same |
| 04/18/2002 | DE10047857A1 Verfahren zur selektiven biokatalytischen Modifizierung von Peptiden und Proteinen Biocatalytic process for the selective modification of peptides and proteins |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425359A1 Dioxolane analogs for improved inter-cellular delivery |
| 04/17/2002 | EP1196782A1 Catalytic anti-factor viii allo-antibodies |
| 04/17/2002 | EP1196442A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 04/17/2002 | EP1196432A2 FVIIa ANTAGONISTS |
| 04/17/2002 | EP1196429A2 Process for the deprotection of protected thiols |
| 04/17/2002 | EP1196184A1 Compositions and methods for treatment of sexual dysfunction |
| 04/17/2002 | EP1007561B1 Novel conjugates of opioids and endogenous carriers |
| 04/17/2002 | EP0918793B1 Inactivating process for lipid envelopped virus, and new antiviral lipopeptides |
| 04/17/2002 | EP0623146B1 Compositions and methods for inhibiting beta-protein function |
| 04/17/2002 | EP0359783B2 Treatment of autoimmune diseases by oral administration of autoantigens |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345333A Echinocandin/carbohydrate complexes |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345301A Improved compounds for protein binding |
| 04/16/2002 | US6372883 For therapy and prophylaxis of infections caused by hepatitis c, hepatitis g and human gb viruses |
| 04/16/2002 | US6372744 β-sheet mimetics and methods relating to the use thereof |
| 04/16/2002 | US6372712 Complex of peptidyl-propyl cis/trans isomerase and drug such as rapamycin, cyclosporin a, fk-506, or other antibiotic |
| 04/16/2002 | US6372474 To deacylate the acyl side chain of a cyclic lipopeptide compound |
| 04/11/2002 | WO2002028895A2 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 04/11/2002 | WO2002028888A2 Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same |
| 04/11/2002 | WO2002028887A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours |
| 04/11/2002 | WO2002028886A2 Caloxins their isolation and use |
| 04/11/2002 | WO2002028438A1 Lipopeptides as absorption enhancers for bioactive compounds |
| 04/11/2002 | WO2002028412A1 Novel use of peptide |
| 04/11/2002 | WO2002028355A2 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | WO2002012275A3 Lat peptides and their use in assays for identifying immunosuppressants |
| 04/11/2002 | WO2002009649A3 Cell internalized peptide-drug conjugates |
| 04/11/2002 | WO2001087323A3 Method for treating cartilage disorders |
| 04/11/2002 | WO2001066147A3 Antimicrobial compounds and formulations |
| 04/11/2002 | WO2001060844A3 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 04/11/2002 | WO2000052048A9 Modulators of beta-amyloid peptide aggregation comprising d-amino acids |
| 04/11/2002 | US20020042102 Synthesis without the use of the cells and their use in vivo as powerful anti-inflammatory, antithrombotic or anti-metastatic compounds |
| 04/11/2002 | DE10048840A1 Verwendung von Lipopeptiden oder Lipoproteinen zur Behandlung von Lungeninfektionen und -tumoren Use of lipopeptides or lipoproteins in the treatment of lung infections and tumors |
| 04/11/2002 | DE10048417A1 Verbindungen mit verzweigtem Linker Compounds with branched linker |
| 04/11/2002 | CA2424543A1 Component for vaccine |
| 04/11/2002 | CA2424506A1 Cyclopeptides, a method for their preparation and their use as inhibitors or activators of angiogenesis |
| 04/11/2002 | CA2424285A1 Use of lipopeptides or lipoproteins for the treatment of lung infections and lung tumours |
| 04/11/2002 | CA2423656A1 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | CA2422092A1 Caloxins their isolation and use |
| 04/10/2002 | EP1195168A2 Ternary radiopharmaceutical complexes |
| 04/10/2002 | EP1194548A1 Novel pyrrhocoricin-derived peptides, and methods of use thereof |
| 04/10/2002 | EP1194531A2 Cyclic peptidomimetic urokinase receptor antagonists |
| 04/10/2002 | EP1194444A2 Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| 04/10/2002 | EP1194164A1 Prion protein peptides and uses thereof |
| 04/10/2002 | EP1194157A1 D-form polypeptide which induces immune tolerance and methods of use |
| 04/10/2002 | EP1161149A4 Ng2/hm proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| 04/10/2002 | EP0752876B1 Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides |
| 04/10/2002 | CN1344321A Screening method |
| 04/10/2002 | CN1344287A Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 04/09/2002 | US6369203 Peptides for the production of preparations for the diagnosis and therapy of systemic lupus |
| 04/09/2002 | US6369193 Contulakin-G, analogs thereof and uses therefor |
| 04/09/2002 | US6369030 Inhibitors of histone acetyltransferases (HATs) and uses thereof |
| 04/09/2002 | US6368877 Self-assembling peptide surfaces for cell patterning and interactions |
| 04/09/2002 | US6368857 Method for provoking proliferation of cytolytic T cells via the use of decapeptides which complex with HLA-A2 molecules |
| 04/09/2002 | US6368852 A peptide capable of inducing cytotoxic t lymphocytes, immune response; anticarcinogenic agents |
| 04/09/2002 | US6368788 Method of treating complications in immunodepressed states resulting from HIV infection |
| 04/09/2002 | CA2298572C Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 04/09/2002 | CA2093219C Amides of antibiotic ge 2270 factors |
| 04/09/2002 | CA2083271C Fibrin binding domain polypeptides and uses and methods of producing same |
| 04/04/2002 | WO2002027315A2 Compounds with a branched linker |
| 04/04/2002 | WO2002026937A1 Chemical substance for protection of brain nerve cell and method for producing thereof |
| 04/04/2002 | WO2002026781A2 Ige receptor antagonists |
| 04/04/2002 | WO2002026778A2 Isolated peptides which bind to hla-c molecules and uses thereof |
| 04/04/2002 | WO2002026777A1 Peptide ligands for prostate specific antigen |
| 04/04/2002 | WO2002026772A1 Method for the selective modification of peptides and proteins |
| 04/04/2002 | WO2001093893A3 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 04/04/2002 | WO2001081421A3 Synthetic peptides that bind to the hepatitis b virus core and e antigens |
| 04/04/2002 | WO2001072846A3 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 04/04/2002 | WO2001072829A3 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 04/04/2002 | CA2423966A1 Peptide ligands for prostate specific antigen |
| 04/04/2002 | CA2421676A1 Method for the selective modification of peptides and proteins |
| 04/04/2002 | CA2420577A1 Peptide-based compounds |
| 04/04/2002 | CA2420475A1 Ige receptor antagonists |
| 04/03/2002 | EP1192178A2 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) |
| 04/03/2002 | EP1192177A1 Statine-derived tetrapeptide inhibitors of beta-secretase |
| 04/03/2002 | EP1191939A1 Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
| 04/03/2002 | EP0894092B1 A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp. |
| 04/03/2002 | CN1343220A Method for producing cyclo-(Asp-Dphe-NMeval-Arg-Gly) |
| 04/03/2002 | CN1343205A Dimeric compounds and as inhibitors of neuraminidase |
| 04/02/2002 | US6365572 For therapy of diseases related to increased or unwanted synthesis of basement membranes such as diabetes mellitus; atherosclerosis; cancer; diabetic retinopathia; fibroplasia retrolentalis; or psoriasis, rheumatoic arthritis |
| 04/02/2002 | US6365571 FGF inhibitor, angiogenesis inhibitor and antitumor agent containing complestatin or its derivative as effective ingredient |
| 04/02/2002 | US6365179 Conjugate having a cleavable linkage for use in a liposome |
| 04/02/2002 | CA1341354C Anticoagulant peptide alcohols |
| 03/28/2002 | WO2002024887A2 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| 03/28/2002 | WO2002024883A2 Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |